DCAF7 anticorps (N-Term)
Aperçu rapide pour DCAF7 anticorps (N-Term) (ABIN928603)
Antigène
Voir toutes DCAF7 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Réactivité croisée
- Souris
-
Purification
- Purified
-
Immunogène
- Dcaf7 antibody was raised in rabbit using the N terminal of Dcaf7 as the immunogen
-
-
-
-
Indications d'application
- Optimal conditions should be determined by the investigator.
-
Commentaires
-
Dcaf7 Blocking Peptide, (ABIN5613131), is also available for use as a blocking control in assays to test for specificity of this Dcaf7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- DCAF7 (DDB1 and CUL4 Associated Factor 7 (DCAF7))
-
Autre désignation
- Dcaf7
-
Sujet
- Dcaf7 is involved in craniofacial development. It acts upstream of the EDN1 pathway and is required for formation of the upper jaw equivalent, the palatoquadrate. The activity required for EDN1 pathway function differs between the first and second arches. It associates with DIAPH1 and controls GLI1 transcriptional activity. It could be involved in skin development. It may function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex. Synonyms: Polyclonal Dcaf7 antibody, Anti-Dcaf7 antibody, DDB1 and CUL4 associated factor 7 antibody, 1700012F10Rik antibody, 2610037L01Rik antibody, C86529 antibody, HAN11 antibody, Wdr68 antibody.
-
Pathways
- SARS-CoV-2 Protein Interactome
Antigène
-